# A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

> **NCT01561053** · PHASE2,PHASE3 · COMPLETED · sponsor: **Instituto Grifols, S.A.** · enrollment: 347 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** Albumin 5%
- **BIOLOGICAL:** Albumin 20%
- **BIOLOGICAL:** Immunoglobulin

## Key facts

- **NCT ID:** NCT01561053
- **Lead sponsor:** Instituto Grifols, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-19
- **Primary completion:** 2018-03-06
- **Final completion:** 2018-03-06
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2019-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01561053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01561053, "A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01561053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*